Aurobindo Pharma surges 19% as Unit IV receives EIR with VAI staus from FDA

The Company has received the Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAl) status from the US Food & Drug Administration (USFDA) for Unit IV.

from Home Page https://ift.tt/2ugn7ja